Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nanocort for Atherosclerotic Plaque Inflammation in PAD
NCT01647685Phase 2Unknown
- Sponsor
- University of Amsterdam
- Start
- May 2012
- Primary completion
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of liposomal prednisolone in atherosclerosis (3 arms), sponsored by University of Amsterdam. Primary endpoint: Quantity of PEG liposomes in the atherosclerotic plaque and/or in atherosclerotic macrophages at Day 0. Status: unknown.
02
Drugs
liposomal prednisolone
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on NCT01647685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01647685.